Astellas Showcases VEOZA™ Data at Major Menopause Congress
Astellas Presents VEOZA™ Data at the International Menopause Conference
Astellas Pharma Inc. is excited to announce that VEOZA™ (fezolinetant), an innovative treatment for managing moderate to severe vasomotor symptoms (VMS) associated with menopause, will be showcased extensively at the International Menopause Society’s World Congress on Menopause. This congress, a significant event for discussing advancements in menopause care and treatments, is anticipated to provide valuable insights into women's health.
Impactful Presentations at the World Congress
The congress will feature a total of six presentations from Astellas, comprising four oral talks and two poster sessions. These presentations are essential for revealing critical data on how VEOZA™ impacts symptoms such as hot flashes and night sweats, which many women experience during menopause.
Focus on Patient-Reported Outcomes
Two key oral presentations from the SKYLIGHT studies will emphasize patient-reported outcomes regarding sleep quality and workplace productivity. The insights from these studies aim to better understand how VEOZA™ can potentially improve quality of life for women experiencing VMS. Presentations will occur during the Menopause New Treatments sessions, scheduled for October 21.
Comprehensive Data Analysis
Additionally, data from the DAYLIGHT study will be discussed, which investigates the effects of VEOZA™ in women who are not suitable for hormone therapy. This exploration is crucial in offering alternative treatment options for a diverse group of women struggling with VMS.
Understanding the Significance of VEOZA™
Astellas's leadership, including Marci English and Emad Siddiqui, expresses their commitment to advancing treatment options for menopausal symptoms. They highlight that the knowledge gained from the presentations will significantly contribute to the understanding of VMS and women's preferences for managing these symptoms.
Details of Specific Presentations
The presentations set to occur at the congress include:
- Findings from the SKYLIGHT 1 and 2 studies, focusing on the impact of VEOZA™ on sleep and productivity at work.
- Daylight study results emphasizing quality of life improvements in women unsuitable for traditional hormone therapies.
- Poster discussions include data indicating no link between VEOZA™ treatment and the occurrence of malignant neoplasms.
- Insights into the new HIGHLIGHT study, designed to evaluate VEOZA™ for women undergoing breast cancer treatment.
About VEOZA™ and Its Mechanism
VEOZA™ is a non-hormonal treatment aimed at addressing menopause-related VMS. It operates by targeting neurokinin 3 (NK3) receptors in the brain, effectively modulating neuronal activity in the hypothalamus—the body’s temperature regulation center to reduce the frequency and severity of hot flashes. With VEOZA™, women now have a promising non-hormonal option for managing their symptoms.
About Astellas Pharma
Astellas Pharma Inc. engages in research and development efforts to provide innovative healthcare solutions tailored to patients’ needs. Operating in over 70 countries, Astellas continuously works to address significant unmet medical needs using its Focus Area Approach, which is committed to delivering new drugs and healthcare solutions that leverage the latest scientific advancements.
Frequently Asked Questions
What is VEOZA™?
VEOZA™ (fezolinetant) is a non-hormonal treatment for moderate to severe vasomotor symptoms related to menopause.
Where will Astellas present VEOZA™ data?
Astellas will feature VEOZA™ at the International Menopause Society's World Congress on Menopause.
What topics will Astellas cover in its presentations?
Topics include patient-reported outcomes on sleep and productivity, quality of life for women unsuitable for hormone therapy, and trial designs for ongoing studies involving fezolinetant.
Is VEOZA™ safe?
Clinical data presented will include safety and efficacy analyses, reflecting its benefits for managing menopausal symptoms.
Who can benefit from VEOZA™?
VEOZA™ is designed for women suffering from moderate to severe vasomotor symptoms during menopause, especially those seeking non-hormonal treatment options.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Celebrate 18 Years of Bierman Autism Centers with Trunk-or-Treat
- Alvotech's AVT03 Receives EMA Marketing Application Acceptance
- Lawsuit Against Social Media Giants for Child Safety Violations
- Bierman Autism Centers Marks 18 Years with Spooky Celebration!
- Massive Security Breach at Internet Archive Exposes Millions
- HONOR Unveils Circle to Search Feature on Magic V3
- Majority of Voters Support Path to Citizenship Strategies
- Strengthening Fraud Protection for the Creator Economy
- IBS Software Empowers Travel Industry with New AI Innovations
- Transformative AI Innovations in Education from Squirrel Ai
Recent Articles
- Huawei’s TECH4ALL Initiative Marks Five Years of Eco-Advancements
- BSS Group Bolsters Digital Commerce in Europe by Acquiring On Tap
- Surge in Foreign Capital Sparks Japanese Stock Market Growth
- GSK Anticipates Share Increase Following Zantac Lawsuit Settlement
- Navigating Economic Trends: Impact on Inflation and Markets
- Market Trends: Sectors Taking Roundabout Paths in New Highs
- SES and Sky Renew Partnership to Enhance Viewer Experience
- Key Market Stocks: Delta Air Lines And Domino's Pizza Updates
- Implantica Secures Strong Support for RefluxStop at AFS 2024
- Japan’s Economic Outlook and Possible Rate Hikes Ahead
- Nikkei 225 Sees Gains as Key Sectors Rally in Japan
- Analyzing the Potential for a Singular Rate Cut by the Fed
- Bullish Nasdaq Signals Strong Potential for Long Investments
- Market Indicators Shift as Nvidia's Influence Diminishes
- Explore Sincethen's Romantic Brand Day Event This October
- Exploring Growth in the Trimethylhydroquinone Market to 2033
- Impressive Growth for VILVI GROUP Sales in September 2024
- BlackRock Finance Inc. Notification on Syensqo Ownership Change
- Essential Updates to Nykredit Realkredit A/S Bonds Information
- Seamlessly Transitioning from Google Photos to iCloud: A Guide
- Exploring Tesla's Robotaxi Potential: Analyst Predictions
- FBI's Innovative Operation Discovers $25M Crypto Fraud Scheme
- profine Group Expands Footprint with EFP International Acquisition
- Fivecast Unveils Discovery Solution to Enhance OSINT Capabilities
- FAW Group Innovates with Digital Transformation Insights
- Hurricane Milton Hits Florida: Category 3 Storm Near Shore
- Fast Retailing Reports 31% Profit Growth, Forecasts Further Rise
- Qatar's Bold Move: Writing Off Loans to Stimulate Growth
- AB Science Reports 2024 Financial Results and Key Developments
- Understanding Bond Replacement for New Lending at Nykredit
- Chinese Market Surges as PBOC Stimulus Propels Stocks Forward
- Join Stora Enso for Their Insightful Q3 2024 Results Webcast
- World Bank Increases South Asia Growth Outlook Amid Demand Surge
- UBS Successfully Integrates Credit Suisse, Says IT Chief
- Chery Expands Production in Russia as Western Plants Close
- Aenitis Technologies Champions Innovation in Bioproduction
- Unlocking Potential: Cornish Metals Secures Financing for Tin Project
- PayPoint Partners with obconnect for New Zealand Banking System
- Avacta Group plc Showcases Innovative Cancer Therapies at Congress
- Renewi plc Finalizes Sale of Its UK Municipal Operations
- Pharming Group to Announce Q3 2024 Financial Results Soon
- Vast Resources plc's Recent Settlement Approval Update
- PayPoint plc's Strategic Share Buyback Revealed
- KBC Group Updates on BlackRock's Stake and Transparency Notice
- Getlink Reports Increased Freight Traffic for September 2024
- H2O.ai Partners with Singtel to Deliver Advanced AI Solutions
- Pharming Group Set to Announce Q3 Financial Results Soon
- Aenitis Champions Innovation in Bioproduction with Acoustofluidic Tech
- Aircall Launches Workspace for Enhanced Communication Tools
- Uber's Electrification Initiatives Ahead of Tesla's Robotaxi Launch